866-997-4948(US-Canada Toll Free)

Head And Neck Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Head and Neck Cancer

No. of Pages : 411 Pages

 

Global Markets Directs, \'Head And Neck Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. 

 

Head And Neck Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Head And Neck Cancer.
  • A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Head And Neck Cancer Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Head And Neck Cancer 13
Head And Neck Cancer Therapeutics under Development by Companies 15
Head And Neck Cancer Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Discovery and Pre-Clinical Stage Products 30
Comparative Analysis 30
Head And Neck Cancer Therapeutics - Products under Development by Companies 31
Head And Neck Cancer Therapeutics - Products under Investigation by Universities/Institutes 38
Companies Involved in Head And Neck Cancer Therapeutics Development 45
Bristol-Myers Squibb Company 45
Johnson & Johnson 46
Boehringer Ingelheim GmbH 47
F. Hoffmann-La Roche Ltd. 48
Shionogi & Co., Ltd. 49
Amgen Inc. 50
Sanofi-Aventis 51
AstraZeneca PLC 52
Eli Lilly and Company 53
Viralytics Ltd. 54
GlaxoSmithKline plc 55
Genentech, Inc. 56
Inovio Biomedical Corporation 57
YM BioSciences Inc. 58
Celltrion, Inc. 59
Millennium Pharmaceuticals, Inc. 60
Novartis AG 61
Ichor Medical Systems, Inc. 62
Daewoong Pharmaceutical Co., Ltd. 63
Eisai Co., Ltd. 64
Pfizer Inc. 65
Takara Holdings Inc. 66
Cell Therapeutics, Inc. 67
Cyclacel Pharmaceuticals Inc. 68
CEL-SCI Corporation 69
Merck KGaA 70
Advaxis, Inc. 71
Neogenix Oncology Corporation 72
Idera Pharmaceuticals, Inc. 73
Bionomics Limited 74
Northwest Biotherapeutics, Inc. 75
Cleveland BioLabs, Inc. 76
Oncolytics Biotech Inc. 77
Oncothyreon Inc 78
Curis, Inc. 79
Transgene SA 80
Jiangsu Hengrui Medicine Co., Ltd. 81
Panacea Biotec Limited 82
Nang Kuang Pharmaceutical Co., Ltd. 83
Nanobiotix 84
PCI Biotech Holding ASA 85
Wilex AG 86
Acceleron Pharma, Inc. 87
Multimmune GmbH 88
Ascenta Therapeutics, Inc. 89
Hawthorn Pharmaceuticals, Inc. 90
PDS Biotechnology Corporation 91
Merrimack Pharmaceuticals, Inc. 92
Jennerex Biotherapeutics, Inc. 93
Oncolys BioPharma Inc. 94
Globeimmune, Inc. 95
Etubics Corporation 96
InteRNA Technologies B.V. 97
Taiwan Liposome Company 98
Cellceutix Corporation 99
VentiRx Pharmaceuticals, Inc. 100
Genelux Corporation 101
IRX Therapeutics, Inc. 102
Northern Therapeutics, Inc. 103
Pique Therapeutics 104
PNP Therapeutics, Inc. 105
ISU ABXIS Co.,Ltd. 106
Jiangsu Kanion Pharmaceutical Co., Ltd. 107
Gliknik, Inc. 108
Coridon Pty Ltd 109
Biotech Pharmaceuticals Co., Ltd. 110
CytomX, LLC. 111
Head And Neck Cancer - Therapeutics Assessment 112
Assessment by Monotherapy Products 112
Assessment by Combination Products 113
Drug Profiles 114
IMO-2055 - Drug Profile 114
cetuximab - Drug Profile 116
cetuximab - Drug Profile 122
vandetanib - Drug Profile 128
brostallicin - Drug Profile 133
paclitaxel poliglumex - Drug Profile 135
dacomitinib - Drug Profile 139
CUDC-101 - Drug Profile 141
panobinostat - Drug Profile 143
dalantercept - Drug Profile 148
PC-A11 + [bleomycin sulfate] - Drug Profile 150
PDS-0101 - Drug Profile 152
DWP-418 - Drug Profile 153
Multikine - Drug Profile 154
Sym-004 - Drug Profile 157
OBP-301 - Drug Profile 158
gefitinib - Drug Profile 159
pemetrexed disodium - Drug Profile 164
litronesib - Drug Profile 170
pexastimogene devacirepvec - Drug Profile 172
CBL-0137 - Drug Profile 174
Reolysin - Drug Profile 175
entolimod - Drug Profile 179
TG-4023 - Drug Profile 181
ADXS-HPV - Drug Profile 183
panitumumab - Drug Profile 186
Cell Based Gene Therapy - Drug Profile 189
P-276 - Drug Profile 190
CVA-21 - Drug Profile 192
IRX-2 - Drug Profile 195
HF-10 - Drug Profile 197
BNC-105 - Drug Profile 198
lapatinib ditosylate - Drug Profile 199
tirapazamine - Drug Profile 201
AT-101 - Drug Profile 202
gefitinib + [cisplatin] + [fluorouracil] + Radiation Therapy - Drug Profile 206
GI-6207 - Drug Profile 208
temsirolimus + [cetuximab] + [cisplatin] - Drug Profile 210
X-379 - Drug Profile 212
celecoxib - Drug Profile 213
erlotinib hydrochloride + [cisplatin] + [docetaxel] - Drug Profile 214
bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] - Drug Profile 216
everolimus - Drug Profile 217
hydroxyurea + [cisplatin] + [docetaxel] + [fluorouracil] - Drug Profile 218
fostamatinib disodium - Drug Profile 267
MLN8237 + Cetuximab + Radiation - Drug Profile 268
Raltegravir + Cisplatin - Drug Profile 270
bevacizumab + [cetuximab] - Drug Profile 271
vandetanib + [cisplatin] + radiation therapy - Drug Profile 272
liposomal lurtotecan dihydrochloride - Drug Profile 274
Haw mAb-12 - Drug Profile 275
PT-207 - Drug Profile 276
EphrinA1 Derived Cytotoxins - Drug Profile 330
Recombinant Delivery Proteins Derived From Interleukin-13 - Drug Profile 331
cetuximab Biosimilar - Drug Profile 332
Head And Neck Cancer Therapeutics - Drug Profile Updates 333
Head And Neck Cancer Therapeutics - Discontinued Products 388
Head And Neck Cancer Therapeutics - Dormant Products 391
 

Appendix 402
Methodology 402
Coverage 402
Secondary Research 402
Primary Research 402
Expert Panel Validation 402
Contact Us 403
Disclaimer 403

List of Table


Number of Products Under Development for Head And Neck Cancer, H1 2013 21
Products under Development for Head And Neck Cancer - Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Development by Companies, H1 2013 (Contd..1) 25
Number of Products under Development by Companies, H1 2013 (Contd..2) 26
Number of Products under Development by Companies, H1 2013 (Contd..3) 27
Number of Products under Development by Companies, H1 2013 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2013 30
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 31
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 32
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 33
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 34
Comparative Analysis by Late Stage Development, H1 2013 35
Comparative Analysis by Mid Clinical Stage Development, H1 2013 36
Comparative Analysis by Early Clinical Stage Development, H1 2013 37
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 38
Products under Development by Companies, H1 2013 39
Products under Development by Companies, H1 2013 (Contd..1) 40
Products under Development by Companies, H1 2013 (Contd..2) 41
Products under Development by Companies, H1 2013 (Contd..3) 42
Products under Development by Companies, H1 2013 (Contd..4) 43
Products under Development by Companies, H1 2013 (Contd..5) 44
Products under Development by Companies, H1 2013 (Contd..6) 45
Products under Investigation by Universities/Institutes, H1 2013 46
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 47
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 48
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 49
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 50
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 51
Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 52
Bristol-Myers Squibb Company, H1 2013 53
Johnson & Johnson, H1 2013 54
Boehringer Ingelheim GmbH, H1 2013 55
F. Hoffmann-La Roche Ltd., H1 2013 56
Shionogi & Co., Ltd., H1 2013 57
Amgen Inc., H1 2013 58
Sanofi-Aventis, H1 2013 59
AstraZeneca PLC, H1 2013 60
Eli Lilly and Company, H1 2013 61
Viralytics Ltd., H1 2013 62
GlaxoSmithKline plc, H1 2013 63
Genentech, Inc., H1 2013 64
Inovio Biomedical Corporation, H1 2013 65
YM BioSciences Inc., H1 2013 66
Celltrion, Inc., H1 2013 67
Millennium Pharmaceuticals, Inc., H1 2013 68
Novartis AG, H1 2013 69
Ichor Medical Systems, Inc., H1 2013 70
Daewoong Pharmaceutical Co., Ltd., H1 2013 71
Eisai Co., Ltd., H1 2013 72
Pfizer Inc., H1 2013 73
Takara Holdings Inc., H1 2013 74
Cell Therapeutics, Inc., H1 2013 75
Cyclacel Pharmaceuticals Inc., H1 2013 76
CEL-SCI Corporation, H1 2013 77
Merck KGaA, H1 2013 78
Advaxis, Inc., H1 2013 79
Neogenix Oncology Corporation, H1 2013 80
Idera Pharmaceuticals, Inc., H1 2013 81
Bionomics Limited, H1 2013 82
Northwest Biotherapeutics, Inc., H1 2013 83
Cleveland BioLabs, Inc., H1 2013 84
Oncolytics Biotech Inc., H1 2013 85
Oncothyreon Inc, H1 2013 86
Curis, Inc., H1 2013 87
Transgene SA, H1 2013 88
Assessment by Monotherapy Products, H1 2013 120
Assessment by Combination Products, H1 2013 121
Head And Neck Cancer Therapeutics - Drug Profile Updates 341
Head And Neck Cancer Therapeutics - Discontinued Products 396
Head And Neck Cancer Therapeutics - Discontinued Products (Contd..1) 397
Head And Neck Cancer Therapeutics - Discontinued Products (Contd..2) 398
Head And Neck Cancer Therapeutics - Dormant Products 399
Head And Neck Cancer Therapeutics - Dormant Products (Contd..1) 400
Head And Neck Cancer Therapeutics - Dormant Products (Contd..2) 401
Head And Neck Cancer Therapeutics - Dormant Products (Contd..3) 402
Head And Neck Cancer Therapeutics - Dormant Products (Contd..4) 403
Head And Neck Cancer Therapeutics - Dormant Products (Contd..5) 404
Head And Neck Cancer Therapeutics - Dormant Products (Contd..6) 405
Head And Neck Cancer Therapeutics - Dormant Products (Contd..7) 406
Head And Neck Cancer Therapeutics - Dormant Products (Contd..8) 407
Head And Neck Cancer Therapeutics - Dormant Products (Contd..9) 408
Head And Neck Cancer Therapeutics - Dormant Products (Contd..10) 409

List of Chart


Number of Products under Development for Head And Neck Cancer, H1 2013 21
Products under Development for Head And Neck Cancer - Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 29
Late Stage Products, H1 2013 35
Mid Clinical Stage Products, H1 2013 36
Early Clinical Stage Products, H1 2013 37
Discovery and Pre-Clinical Stage Products, H1 2013 38
Assessment by Monotherapy Products, H1 2013 120
Assessment by Combination Products, H1 2013 121

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *